Response to Jani et al et al . A prospective, randomized, doubleblind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

Kane Barry

首页> 外文期刊>International journal of rheumatic diseases >Response to Jani et al et al . A prospective, randomized, doubleblind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

【24h】

Response to Jani et al et al . A prospective, randomized, doubleblind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

机译：回应Jani等人。前瞻性，随机，双卷发，多期，并行组，活性控制研究，用于比较生物仿毒性Adalimalab（exemptia; Zrc-3197）和患者患者的疗效和安全性患者类风湿性关节炎患者的疗效和安全性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International journal of rheumatic diseases》 |2017年第11期|共1页
作者
Kane Barry;
展开▼
作者单位

Rheumatology DepartmentConcord Repatriation General HospitalConcord New South Wales Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类全身性疾病;
关键词

相似文献

外文文献
中文文献

1. Response to Jani et al et al . A prospective, randomized, doubleblind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis [J] . Kane Barry International journal of rheumatic diseases . 2017,第Suppla1期

机译：回应Jani等人。前瞻性，随机，双卷发，多期，并行组，活性控制研究，用于比较生物仿毒性Adalimalab（exemptia; Zrc-3197）和患者患者的疗效和安全性患者类风湿性关节炎患者的疗效和安全性
2. A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC ZRC ‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis [J] . Jani Rajendrakumar H., Gupta Rajiv, Bhatia Girish, International journal of rheumatic diseases . 2016,第Suppla2期

机译：前瞻性，随机，双盲，多期，并联，主动对照研究，用于比较生物仿制性Adalimalab（exemptia; ZRC Zrc -3197）和类毒素关节炎患者的疗效和安全性的疗效和安全性
3. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis [J] . Jani Rajendrakumar H., Gupta Rajiv, Bhatia Girish, International journal of rheumatic diseases . 2016,第11期

机译：一项前瞻性，随机，双盲，多中心，平行组，主动对照研究，用于比较生物仿制药阿达木单抗（豁免; ZRC-3197）和阿达木单抗（Humira）在类风湿性关节炎中的疗效和安全性
4. No adverse physiological responses to infrared whole body hyperthermia in patients with rheumatoid arthritis and ankylosing spondylitis compared to healthy subjects. [C] . F.G.J. OOSTERVELD, E. KOOPMAN, J. OLDE SCHOLTENHUIS, Advances in biomedical research . 2010

机译：与健康受试者相比，类风湿性关节炎和强直性脊柱炎患者对红外全身热疗没有不利的生理反应。
5. A prospective, multicentre, randomized, controlled clinical investigation of dermagraft in patients with venous leg ulcers. [D] . Al-Muhairi, Amna Suhail. 2004

机译：静脉曲张溃疡患者皮肤移植的前瞻性，多中心，随机对照临床研究。
6. A prospective randomized double‐blind multicentre parallel‐group active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis [O] . Rajendrakumar H. Jani, Rajiv Gupta, Girish Bhatia, -1

机译：一项前瞻性随机双盲多中心平行组主动对照研究以比较生物仿制药阿达木单抗（Exemptia； ZRC-3197）和阿达木单抗（Humira）在类风湿性关节炎中的疗效和安全性
7. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA (R)) to the reference product (Humira (R)) in patients with active rheumatoid arthritis [O] . Jamshidian A., Gharibdoost F., Vojdanian M., 2017

机译：一项III期随机，两臂，双盲，平行，主动控制和非劣效性临床试验，用于比较生物仿制药阿达木单抗（CinnoRA（R））与参比产品（Humira（R））的疗效和安全性。活动性类风湿关节炎患者

Response to Jani et al et al . A prospective, randomized, doubleblind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

著录项

相似文献

相关主题

期刊订阅